Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) on Tuesday, plunged -1.04% from the previous trading day, before settling in for the closing price of $14.47. Within the past 52 weeks, RDY’s price has moved between $12.90 and $16.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 8.97% annually for the last half of the decade. The company achieved an average annual earnings per share of 2.09%. With a float of $834.06 million, this company’s outstanding shares have now reached $834.38 million.
In an organization with 27048 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 59.29%, operating margin of 22.52%, and the pretax margin is 24.1%.
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Insider Updates
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Dr. Reddy’s Laboratories Ltd. ADR is 0.00%, while institutional ownership is 14.46%. The most recent insider transaction that took place on Jul 29 ’24, was worth 5,390,000.
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 16.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.74% during the next five years compared to 20.07% growth over the previous five years of trading.
Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) Trading Performance Indicators
Dr. Reddy’s Laboratories Ltd. ADR (RDY) is currently performing well based on its current performance indicators. A quick ratio of 1.36 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.32. Likewise, its price to free cash flow for the trailing twelve months is 87.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.77, a number that is poised to hit 0.22 in the next quarter and is forecasted to reach 0.81 in one year’s time.
Technical Analysis of Dr. Reddy’s Laboratories Ltd. ADR (RDY)
Let’s dig in a bit further. During the last 5-days, its volume was 1.36 million. That was better than the volume of 1.06 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 69.94%. Additionally, its Average True Range was 0.25.
During the past 100 days, Dr. Reddy’s Laboratories Ltd. ADR’s (RDY) raw stochastic average was set at 13.31%, which indicates a significant decrease from 49.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 17.57% in the past 14 days, which was lower than the 20.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.00, while its 200-day Moving Average is $15.14. However, in the short run, Dr. Reddy’s Laboratories Ltd. ADR’s stock first resistance to watch stands at $14.38. Second resistance stands at $14.45. The third major resistance level sits at $14.49. If the price goes on to break the first support level at $14.27, it is likely to go to the next support level at $14.23. Assuming the price breaks the second support level, the third support level stands at $14.16.
Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) Key Stats
Market capitalization of the company is 11.94 billion based on 834,701K outstanding shares. Right now, sales total 3,350 M and income totals 668,000 K. The company made 953,930 K in profit during its latest quarter, and 149,380 K in sales during its previous quarter.
